Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Hung-Hsien Chiang, Deng-Chyang Wu, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Chih-Chien Yao, Cheng-En Tsai, Chih-Ming Liang, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang & Seng-Kee Chuah. (2019) Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. Drug Design, Development and Therapy 13, pages 1347-1356.
Read now
Read now
Wei-Chen Tai, Chih-Ming Liang, Kuo-Wei Bi, Chung-Mou Kuo, Lung-Sheng Lu, Cheng-Kun Wu, Shih-Cheng Yang, Yuan-Hung Kuo, Chen-Hsiang Lee, Chih-Fang Huang, Chien-Ning Hsu, Pin-I Hsu, Deng-Chyang Wu, Tsung-Hui Hu, Keng-Liang Wu & Seng-Kee Chuah. (2019) A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial. Infection and Drug Resistance 12, pages 2923-2931.
Read now
Read now
Michael Kukulka, Sai Nudurupati & Maria Claudia Perez. (2018) Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe. Clinical and Experimental Gastroenterology 11, pages 381-389.
Read now
Read now
Joseph Mermelstein, Alanna Chait Mermelstein & Maxwell M Chait. (2016) Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clinical and Experimental Gastroenterology 9, pages 163-172.
Read now
Read now
Jeanetta W Frye & David A Peura. (2015) Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR. Therapeutics and Clinical Risk Management 11, pages 1649-1656.
Read now
Read now
Ege Altan, Kathleen Blondeau, Ans Pauwels, Ricard Farré & Jan Tack. (2012) Evolving pharmacological approaches in gastroesophageal reflux disease. Expert Opinion on Emerging Drugs 17:3, pages 347-359.
Read now
Read now
Articles from other publishers (22)
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim & Kyun-Seop Bae. (2022) Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut and Liver 17:1, pages 92-99.
Crossref
Crossref
Rui Dai, Alan A. Sag, Jonathan G. Martin, Nicholas T. Befera, Waleska M. Pabon-Ramos, Paul V. Suhocki, Tony P. Smith, Charles Y. Kim, Andrew J. Muir & James Ronald. (2021) Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. Clinical Imaging 77, pages 187-192.
Crossref
Crossref
I. G. Pakhomova, G. Yu. Knorring, T. N. Kochegura & E. Yu. Pavlova. (2021) Differentiated approach to the choice of PPI in a patient with GERD in the practice of an outpatient (with a clinical case). Meditsinskiy sovet = Medical Council:21, pages 118-125.
Crossref
Crossref
Xi‐Hsuan Lin, Jiing‐Chyuan Luo, Po‐Hsiang Ting, Tien‐En Chang, Yi‐Hsiang Huang, Ming‐Chih Hou & Fa‐Yauh Lee. (2020) Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. Journal of Gastroenterology and Hepatology 35:12, pages 2096-2102.
Crossref
Crossref
Phillip Ryan, Adesola Odunayo, Josh Price, Silke Hecht, Shanna Hillsman, Gina Galyon, Joerg Steiner & M. Katherine Tolbert. (2020)
Comparative analysis of the effect of PO administered acid suppressants on gastric
pH
in healthy cats
. Journal of Veterinary Internal Medicine 34:5, pages 1879-1885.
Crossref
Crossref
I. V. Maev, J. V. Selskaya, D. N. Andreev, D. T. Dicheva, Z. N. Bogolepova & E. I. Kuznetsova. (2019) Laryngopharyngeal reflux: clinical significance, modern approaches to diagnosis and treatment. Medical Council:3, pages 8-16.
Crossref
Crossref
Sabine Roman & Peter J. Kahrilas. 2019. Evidence-based Gastroenterology and Hepatology 4e. Evidence-based Gastroenterology and Hepatology 4e
1
20
.
Douglas S. Lewis, Tzu-Hao Lee, Meghana Konanur, Cole Ziegler, Melissa D. Hall, Waleska M. Pabon-Ramos, Paul V. Suhocki, Tony P. Smith, Charles Y. Kim, Steven S. Choi & James Ronald. (2019) Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 30:2, pages 163-169.
Crossref
Crossref
V. O. Kaibysheva, S. V. Kashin, L. M. Mikhaleva, N. S. Vidyayeva, R. O. Kuvaev, Z. V. Galkova, T. A. Ilchishina, V. V. Pechnikova, E. L. Nikonov & S. G. Shapovaliyants. (2019) Eosinophilic esophagitis: current view on the problem and own clinical observations. Dokazatel'naya gastroenterologiya 8:1, pages 58.
Crossref
Crossref
Linda Luo, Xiaoli Wen, Yueying Du, Zhen Jiang & Xingjie Guo. (2018) Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study. Biomedical Chromatography 32:11, pages e4345.
Crossref
Crossref
V. I. Simanenko, S. V. Tikhonov & N. B. Lishchuk. (2018) Octurnal heartburn: there is a solution. Medical Council:14, pages 18-23.
Crossref
Crossref
E. K. Stern, D. A. Carlson, S. Falmagne, A. D. Hoffmann, M. Carns, J. E. Pandolfino, M. Hinchcliff & D. M. Brenner. (2018) Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterology & Motility 30:2, pages e13247.
Crossref
Crossref
Chih-Ming Liang, Ming-Te Kuo, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Hsing-Ming Wang, Chih-Chien Yao, Cheng-En Tsai, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang & Deng-Chyang Wu. (2017) First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World Journal of Gastroenterology 23:47, pages 8395-8404.
Crossref
Crossref
Benjamin D. Gold, Betsy Pilmer, Jaroslaw Kierkuś, Barbara Hunt, Maria Claudia Perez & David Gremse. (2017) Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease. Digestive Diseases and Sciences 62:11, pages 3059-3068.
Crossref
Crossref
Mei-Juan Li, Qing Li, Min Sun & Li-Qin Liu. (2017) Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. Medicine 96:39, pages e8120.
Crossref
Crossref
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai & Kazuyoshi Otake. (2016) Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics 168, pages 12-22.
Crossref
Crossref
Khean Lee Goh, Myung Gyu Choi, Ping I Hsu, Hoon Jai Chun, Varocha Mahachai, Udom Kachintorn, Somchai Leelakusolvong, Nayoung Kim, Abdul Aziz Rani, Benjamin C Y Wong, Justin Wu, Cheng Tang Chiu, Vikram Shetty, Joseph C Bocobo, Melchor M Chan & Jaw-Town Lin. (2016) Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. Journal of Neurogastroenterology and Motility 22:3, pages 355-366.
Crossref
Crossref
Deng-Chyang Wu, Chao-Hung Kuo, Feng-Woei Tsay, Wen-Hung Hsu, Angela Chen & Ping-I Hsu. (2016) A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine 95:11, pages e2698.
Crossref
Crossref
Luning Sun, Yang Cao, Huiwen Jiao, Yunqian Fang, Zhicheng Yang, Mingliang Bian, Hongwen Zhang, Xiaojian Gong & Yongqing Wang. (2015)
Enantioselective determination of (
R
)- and (
S
)-lansoprazole in human plasma by chiral liquid chromatography with mass spectrometry and its application to a stereoselective pharmacokinetic study
. Journal of Separation Science 38:21, pages 3696-3703.
Crossref
Crossref
Dustin A. Carlson, Monique Hinchcliff & John E. Pandolfino. (2014) Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. Current Rheumatology Reports 17:1.
Crossref
Crossref
M. S. Wu, S. C. Tan & T. Xiong. (2013) Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics 38:2, pages 190-201.
Crossref
Crossref
Jai Moo Shin & Nayoung Kim. (2013) Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors. Journal of Neurogastroenterology and Motility 19:1, pages 25-35.
Crossref
Crossref